Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : Founders Financial Securities adds Bristol-Myers Squibb Co to its portfolio

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2017 | 05:22pm CET

Founders Financial Securities added new position in Bristol-Myers Squibb Co during the most recent quarter end. The investment management firm now holds 5,912 shares of Bristol-Myers Squibb Co which is valued at $353,124 , the company said in a statement filed on Jan 10, 2017 with the SEC.Bristol-Myers Squibb Co makes up approximately 0.14% of Founders Financial Securitiess portfolio.

Other Hedge Funds, Including , Carlton Hofferkamp Jenks Wealth Management boosted its stake in BMY in the latest quarter, The investment management firm added 1,800 additional shares and now holds a total of 7,900 shares of Bristol-Myers Squibb Co which is valued at $471,867. Bristol-Myers Squibb Co makes up approx 0.34% of Carlton Hofferkamp Jenks Wealth Managements portfolio.Integrated Wealth Management reduced its stake in BMY by selling 1,369 shares or 9.52% in the most recent quarter. The Hedge Fund company now holds 13,018 shares of BMY which is valued at $780,429. Bristol-Myers Squibb Co makes up approx 0.29% of Integrated Wealth Managements portfolio.Eqis Capital Management boosted its stake in BMY in the latest quarter, The investment management firm added 7,653 additional shares and now holds a total of 23,659 shares of Bristol-Myers Squibb Co which is valued at $1,422,616. Bristol-Myers Squibb Co makes up approx 0.09% of Eqis Capital Managements portfolio.First American Trust Fsb boosted its stake in BMY in the latest quarter, The investment management firm added 15,086 additional shares and now holds a total of 103,916 shares of Bristol-Myers Squibb Co which is valued at $6,177,806. Bristol-Myers Squibb Co makes up approx 1.90% of First American Trust Fsbs portfolio.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Bristol-Myers Squibb Co closed down -0.25 points or -0.44% at $56.55 with 99,77,917 shares getting traded on Thursday. Post opening the session at $56.5, the shares hit an intraday low of $56.015 and an intraday high of $56.78 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the companys financial health, Bristol-Myers Squibb Co reported $0.77 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $0.65. The company had revenue of $4922.00 million for the quarter, compared to analysts expectations of $4796.98 million. The companys revenue was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.39 EPS.

Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Upgraded by Jefferies to Buy on Dec 19, 2016. Shares were Reiterated by Deutsche Bank on Oct 28, 2016 to Hold and Lowered the Price Target to $ 52 from a previous price target of $59 .

(c) 2017 2016 AIN. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
01/14 BRISTOL MYERS SQUIBB : Founders Financial Securities adds Bristol-Myers Squibb C..
01/12 BRISTOL MYERS SQUIBB : Janssen Enters Immunotherapy Clinical Collaboration with ..
01/12 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Have Provided New Infor..
01/12 BRISTOL MYERS SQUIBB : to Present at J.P. Morgan Healthcare Conference
01/12 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Discuss Findings in..
01/12 BRISTOL MYERS SQUIBB : Details Findings in Medicinal Chemistry (Difluorocyclobut..
01/12 BRISTOL MYERS SQUIBB : Data on Biosensing Reported by Researchers at Bristol-Mye..
01/12 BRISTOL MYERS SQUIBB : Announces Immunotherapy Clinical Collaboration with Janss..
01/12 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Provides New Data on H..
01/12 BRISTOL MYERS SQUIBB : Investigators from Bristol-Myers Squibb Release New Data ..
More news
Sector news : Pharmaceuticals - NEC
08:11pDJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- Update
08:01pDJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says
07:42p Bayer, Monsanto confirm spending plans after meeting Trump
06:40pDJSHIRE : Files 8K - Other Events
04:01pDJBIOGEN : Reaches Settlement and License Agreement for MS Drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/13 BIOTECHS : What The 'Trump Dump' And CVS's EpiPen Move May Mean
01/12 Merck gets upgrades on leadership in drug/chemo combo race
01/11 Allergan CEO also has a Twitter account
01/11 JPMorgan Day Two Roundup - All Talk, Very Little Action
01/11 Merck Muscles Into Bristol's Combo Space
Advertisement
Financials ($)
Sales 2016 19 320 M
EBIT 2016 5 355 M
Net income 2016 4 639 M
Debt 2016 175 M
Yield 2016 2,78%
P/E ratio 2016 20,38
P/E ratio 2017 19,98
EV / Sales 2016 4,87x
EV / Sales 2017 4,67x
Capitalization 93 957 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 62,5 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-3.80%93 957
JOHNSON & JOHNSON-0.53%311 773
ROCHE HOLDING LTD.2.75%203 077
PFIZER INC.0.12%197 343
NOVARTIS AG-1.48%187 856
MERCK & CO., INC.5.89%171 880
More Results